Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.

[1]  Vernon M. Chinchilli,et al.  β-Adrenergic Receptor Polymorphisms and Response to Salmeterol , 2006 .

[2]  E. Israel,et al.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.

[3]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[4]  P. Dorinsky,et al.  Retrospective review of studies shows that patients receiving salmeterol plus an ICS have fewer serious asthma exacerbations versus patients on an ICS alone, regardless of ethnic origin☆ , 2004 .

[5]  N. Laird,et al.  Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. , 2003, The Journal of allergy and clinical immunology.

[6]  B. Kobilka,et al.  Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox , 2003 .

[7]  S. Liggett,et al.  Update on current concepts of the molecular basis of beta2-adrenergic receptor signaling. , 2002, The Journal of allergy and clinical immunology.

[8]  R. Panettieri.  Airway smooth muscle: an immunomodulatory cell. , 2002, The Journal of allergy and clinical immunology.

[9]  L. Palmer,et al.  Pharmacogenetics of asthma. , 2002, American journal of respiratory and critical care medicine.

[10]  J. O'donnell,et al.  Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. , 2002, Chest.

[11]  J. O'donnell,et al.  Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. , 2002, The Journal of allergy and clinical immunology.

[12]  P. Dorinsky,et al.  Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  A Tattersfield,et al.  Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. , 2001, American journal of respiratory and critical care medicine.

[14]  P. Dorinsky,et al.  Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone. , 2001, American journal of respiratory and critical care medicine.

[15]  A. Sandford,et al.  β2-Adrenergic receptor polymorphisms and asthma , 2001 .

[16]  S. Liggett,et al.  α2A/α2C-Adrenergic Receptor Third Loop Chimera Show That Agonist Interaction with Receptor Subtype Backbone Establishes G Protein-coupled Receptor Kinase Phosphorylation* , 2000, The Journal of Biological Chemistry.

[17]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Drazen,et al.  Asthma exacerbations during long term â agonist use : influence of â 2 adrenoceptor polymorphism , 2000 .

[19]  E. Silverman,et al.  The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. , 2000, American journal of respiratory and critical care medicine.

[20]  S. Shrewsbury,et al.  Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) , 2000, BMJ : British Medical Journal.

[21]  S. Liggett.  β2-Adrenergic Receptor Pharmacogenetics , 2000 .

[22]  B. Dickey,et al.  Long-acting Inhaled β2-Agonists in Asthma Therapy , 1998 .

[23]  R. Hancox,et al.  Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. , 1998, The European respiratory journal.

[24]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[25]  I. Hall,et al.  Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. , 1995, American journal of respiratory cell and molecular biology.

[26]  I. Hall,et al.  Association of Glu 27 β2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects , 1995, The Lancet.

[27]  S. Green,et al.  A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.

[28]  S. Liggett,et al.  Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. , 1993, American journal of respiratory cell and molecular biology.

[29]  J Crane,et al.  Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. , 1991, Thorax.

[30]  C. Print,et al.  Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.

[31]  R. Dixon,et al.  cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Rubin,et al.  Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .